TD Asset Management Inc Boosts Stock Position in Caris Life Sciences, Inc. $CAI

TD Asset Management Inc raised its stake in Caris Life Sciences, Inc. (NASDAQ:CAI) by 248.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 773,852 shares of the company’s stock after purchasing an additional 551,516 shares during the period. TD Asset Management Inc owned 0.27% of Caris Life Sciences worth $20,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in CAI. Diversified Trust Co. acquired a new stake in Caris Life Sciences in the fourth quarter worth about $540,000. Olistico Wealth LLC acquired a new stake in Caris Life Sciences in the fourth quarter worth about $31,000. Zevenbergen Capital Investments LLC acquired a new stake in Caris Life Sciences in the fourth quarter worth about $14,655,000. Hamilton Lane Advisors LLC acquired a new stake in Caris Life Sciences in the fourth quarter worth about $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Caris Life Sciences by 26.5% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock worth $2,032,000 after acquiring an additional 15,778 shares in the last quarter.

Caris Life Sciences Price Performance

Caris Life Sciences stock opened at $16.49 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.05 and a quick ratio of 6.52. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The firm has a market capitalization of $4.66 billion and a P/E ratio of -2.17. The business’s 50-day moving average price is $17.85.

Insider Activity at Caris Life Sciences

In other news, Director Jeff L. Vacirca bought 31,050 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $16.15 per share, with a total value of $501,457.50. Following the completion of the acquisition, the director directly owned 49,671 shares of the company’s stock, valued at $802,186.65. This trade represents a 166.75% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 50.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CAI. Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Wolfe Research downgraded Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Jefferies Financial Group began coverage on Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 price target for the company. Canaccord Genuity Group lowered their price target on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a report on Friday, March 13th. Finally, Citigroup lowered their price target on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Caris Life Sciences currently has an average rating of “Hold” and an average target price of $27.56.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.